Drugs / ELPAMOTIDE
ELPAMOTIDE
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00639925 | Mar 2007 → Mar 2013 | malignant pancreatic neoplasm | Fukushima Medical University | Unknown | No outcome recorded |
| Phase 1 | NCT00622622 | Nov → Dec 2006 | malignant pancreatic neoplasm | Wakayama Medical University | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00655785 | Sep 2007 → Mar 2013 | malignant pancreatic neoplasm | Fukushima Medical University | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ELPAMOTIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108295 ↗ |
| Known as | Elpamotida | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108295 ↗ |
| Known as | VEGFR2-169 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00622622 ↗ |
| Known as | Vegfr2-169 peptide vaccine | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108295 ↗ |
| Modality | Peptide | “The VEGFR2-169 peptide was subcutaneously injected weekly in a dose-escalation manner” PMID 19930156 ↗ Oct 2009 |
| Route | Subcutaneous | “The VEGFR2-169 peptide was subcutaneously injected weekly” PMID 19930156 ↗ Oct 2009 |